March 17, 2022
InSysBio team is going to present its posters in frames of American Association for Cancer Research (AACR) Annual Meeting 2022 which is to be held April 8-13, New Orleans, Louisiana. The abstracts have been published on AACR website and E-Posters are going to be presented if frames of Poster Sessions:
April 8, 2022, 12:00 PM - 1:00 PM
(Session OPO.ET05.01 - Pharmacology, Pharmacogenetics, and Pharmacogenomics)
Affiliation: (1) InSysBio, Moscow, Russia; (2) BeiGene USA, Inc., San Mateo, CA; (3) BeiGene (Beijing) Co., Ltd. Beijing, China; (4) BeiGene (Shanghai) Co., Ltd., Shanghai, China
(Session OPO.BCS02.01 - Convergence Science and Systems Biology)
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | December 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Dec 2019 15:35
InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
